Jpmorgan Chase & CO Horizon Therapeutics Public LTD CO Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$98.98 - $115.74 $44.4 Million - $52 Million	-448,947 Reduced 8.18%	5,042,293 $583 Million
Q2 2023 Aug 11, 2023	BUY	$96.34 - $112.38 $430,543 - $502,226	4,469 Added 0.08%	5,491,240 $565 Million
Q1 2023 May 18, 2023	BUY	$107.32 - $113.5 $1 Million - $1.06 Million	9,362 Added 0.17%	5,486,771 $599 Million
Q1 2023 May 11, 2023	SELL	$107.32 - $113.5 $619 Million - $655 Million	-5,771,480 Reduced 51.31%	5,477,409 $598 Million
Q4 2022 Feb 13, 2023	BUY	$62.39 - $113.8 $278 Million - $508 Million	4,461,247 Added 65.73%	11,248,889 $1.28 Billion
Q3 2022 Nov 14, 2022	BUY	$58.92 - $84.67 $7.96 Million - $11.4 Million	135,113 Added 2.03%	6,787,642 $420 Million
Q2 2022 Aug 11, 2022	BUY	$79.4 - $116.36 $42.4 Million - $62.1 Million	534,050 Added 8.73%	6,652,529 $531 Million
Q1 2022 May 11, 2022	BUY	$86.42 - $109.81 $3.24 Million - $4.12 Million	37,525 Added 0.62%	6,118,479 $644 Million
Q4 2021 Feb 10, 2022	BUY	$98.56 - $119.91 $26.3 Million - $32 Million	266,724 Added 4.59%	6,080,954 $655 Million
Q3 2021 Nov 12, 2021	BUY	$91.91 - $110.37 $534 Million - $642 Million	5,814,230 New	5,814,230 $637 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.